Beta Bionics, Inc. - Common Stock (BBNX)

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.

Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.

Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform. Speaking at a Bank of

Beta Bionics BBNX Q1 2026 Earnings Transcript

Beta Bionics (BBNX) Q4 2025 Earnings Transcript

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Beta Bionics (BBNX) Q3 2025 Earnings Transcript

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Beta Bionics (BBNX) beat Q3 2025 revenue estimates and raised its full-year guidance. The medical device company reported strong user growth and a narrower-than-expected loss.